It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...

Ethicists often debate how to understand reasonable risk. But it is widely agreed that reasonable risks must be minimised to ...

Understanding how human neurons cope with the energy demands of a large, active brain could open up new avenues for treating ...

Can we really achieve immortality? Explore the latest scientific breakthroughs, ethical dilemmas, and what the future might ...

On the wall of Dian Yang's office hangs a painting of a "Pandora's box of cancer" being opened with a molecular key. From ...

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report), ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

In this study, the investigators used the CRISPR gene editing tool to delete various genetic sequences, and identified about ...